Activation and inhibition of adenylyl cyclase isoforms by forskolin analogs

Journal of Pharmacology and Experimental Therapeutics

Volumn 325, Issue 1, 2008, Pages 27-36

  Pinto, Cibele ^a   Papa, Dan ^a   Hübner, Melanie ^b   Mou, Tung Chung ^c   Lushington, Gerald H ^a   Seifert, Roland ^b  

^a UNIVERSITY OF KANSAS   (United States)

^b UNIVERSITY OF REGENSBURG   (Germany)

^c UNIVERSITY OF MONTANA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 DEOXYFORSKOLIN; 1,9 DIDEOXYFORSKOLIN; 6 ACETYL 7 DEACETYLFORSKOLIN; 7 DEACETYL 1 DEOXYFORSKOLIN; 7 DEACETYL 1,9 DIDEOXYFORSKOLIN; 7 DEACETYL 7 (N METHYLPIPERAZINO GAMMA BUTYRYLOXY)FORSKOLIN; 7 DEACETYLFORSKOLIN; 9 DEOXYFORSKOLIN; ADENYLATE CYCLASE; ADENYLATE CYCLASE 1; ADENYLATE CYCLASE 2; ADENYLATE CYCLASE 5; BODIPY FORSKOLIN; DITERPENE; FORSKOLIN; FORSKOLIN DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DRUG BINDING SITE; DRUG POTENCY; ENZYME ACTIVATION; ENZYME ACTIVE SITE; ENZYME PURIFICATION; INSECT CELL; LEPIDOPTERA; MOLECULAR MODEL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADENYLATE CYCLASE; ANIMALS; CELL LINE; DITERPENES; DOGS; DRUG DESIGN; ENZYME ACTIVATION; ENZYME INHIBITORS; FORSKOLIN; ISOENZYMES; MICE; STRUCTURE-ACTIVITY RELATIONSHIP; TRANSFECTION;

EID: 41149107453     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.107.131904     Document Type: Article

References (38)

1. Bach ME, Barad M, Son H, Zhuo M, Lu YF, Shih R, Mansuy I, Hawkins RD, and Kandel ER (1999) Age-related defects in spatial memory are correlated with defects in the late phase of hippocampal long-term potentiation in vitro and are attenuated by drugs that enhance the cAMP signaling pathway. Proc Natl Acad Sci U S A 96:5280-5285.
2. Birnbaumer L, Abramowitz J, and Brown AM (1990) Receptor-effector coupling by G proteins. Biochim Biophys Acta 1031:163-224.
3. Clark M, Cramer RD III, and van Opdenbosch N (1989) Validation of the general purpose Tripos 5.2 force field. J Comput Chem 10:982-1012.
4. Dessauer CW, Scully TT, and Gilman AG (1997) Interactions of forskolin and ATP with the cytosolic domains of mammalian adenylyl cyclase. J Biol Chem 272:22272-22277.
5. Dessauer CW, Tesmer JJ, Sprang SR, and Gilman AG (1999) The interactions of adenylate cyclases with P-site inhibitors. Trends Pharmacol Sci 20:205-210.
6. Ding X and Staudinger JL (2005) Induction of drug metabolism by forskolin: the role of the pregnane X receptor and the protein kinase A signal transduction pathway. J Pharmacol Exp Ther 312:849-856.
7. Gasteiger J and Marsili M (1980) Iterative partial equalization of orbital electronegativity: a rapid access to atomic charges. Tetrahedron 36:3219-3228.
8. sα proteins in Sf9 insect cells: limitations in comparison with fusion proteins. Biochim Biophys Acta 1613:101-114.
9. Gille A, Lushington GH, Mou TC, Doughty MB, Johnson RA, and Seifert R (2004) Differential inhibition of adenylyl cyclase isoforms and soluble guanylyl cyclase by purine and pyrimidine nucleotides. J Biol Chem 279:19955-19969.
10. Hanoune J and Defer N (2001) Regulation and role of adenylyl cyclase isoforms. Annu Rev Pharmacol Toxicol 41:145-174.
11. Iwatsubo K, Okumura S, and Ishikawa Y (2006) Drug therapy aimed at adenylyl cyclase to regulate cyclic nucleotide signaling. Endocr Metab Immune Disord Drug Targets 6:239-247.
12. Kenakin T (2001) Inverse, protean, and ligand-selective agonism: matters of receptor conformation. FASEB J 15:598-611.
13. Kenakin T (2002) Drug efficacy at G protein-coupled receptors. Annu Rev Pharmacol Toxicol 42:349-379.
14. Kenakin T, Jenkinson S, and Watson C (2006) Determining the potency and molecular mechanism of action of insurmountable antagonists. J Pharmacol Exp Ther 319:710-723.
15. Kobilka BK (2007) G protein coupled receptor structure and activation (2007). Biochim Biophys Acta 1768:794-807.
16. Laurenza A, Khandelwal Y, De Souza NJ, Rupp RH, Metzger H, and Seamon KB (1987) Stimulation of adenylate cyclase by water-soluble analogues of forskolin. Mol Pharmacol 32:133-139.
17. Laurenza A, Sutkowski EM, and Seamon KB (1989) Forskolin: a specific stimulator of adenylyl cyclase or a diterpene with multiple sites of action? Trends Pharmacol Sci 10:442-447.
18. Liu CY, Zhang H, and Christofi FL (1998) Adenylyl cyclase co-distribution with the CaBPs, calbindin-D28 and calretinin, varies with cell type: assessment with the fluorescent dye, BODIPY forskolin, in enteric ganglia. Cell Tissue Res 293:57-73.
19. Mou T-C, Gille A, Suryanarayana S, Richter M, Seifert R, and Sprang SR (2006) Broad specificity of mammalian adenylyl cyclase for interaction with 2′3′-substituted purine- and pyrimidine nucleotide inhibitors. Mol Pharmacol 70:878-886.
20. Onda T, Hashimoto Y, Nagai M, Kuramochi H, Saito S, Yamazaki H, Toya Y, Sakai I, Homcy CJ, Nishikawa K, et al. (2001) Type-specific regulation of adenylyl cyclase: selective pharmacological stimulation and inhibition of adenylyl cyclase isoforms. J Biol Chem 276:47785-47793.
21. Penn RB, Pronin AN, and Benovic JL (2000) Regulation of G protein-coupled receptor kinases. Trends Cradiovasc Med 10:81-89.
22. Pieroni JP, Harry A, Chen J, Jacobowitz O, Magnusson RP, and Iyengar R (1995) Distinct characteristics of the basal activities of adenylyl cyclases 2 and 6. J Biol Chem 270:21368-21373.
23. Putnam WC, Swenson SM, Reif GA, Wallace DP, Helmkamp GM Jr, and Grantham JJ (2007) Identification of a forskolin-like molecule in human renal cysts. J AmSoc Nephrol 18:934-943.
24. Robbins JD, Boring DL, Tang WJ, Shank R, and Seamon KB (1996) Forskolin carbamates: binding and activation studies with type I adenylyl cyclase. J Med Chem 39:2745-2752.
25. Rottlaender D, Matthes J, Vatner SF, Seifert R, and Herzig S (2007) Functional adenylyl cyclase inhibition in murine cardiomyocytes by 2′(3′)-O-(N-methylanthraniloyl)-guanosine 5′-[γ-thio] triphosphate. J Pharmacol Exp Ther 321:608-615.
26. Seamon KB and Daly JW (1986) Forskolin: its biological and chemical properties. Adv Cyclic Nucleotide Protein Phosphorylation Res 20:1-150.
27. Seamon KB, Daly JW, Metzger H, de Souza NJ, and Reden J (1983) Structure-activity relationships for activation of adenylate cyclase by the diterpene forskolin and its derivatives. J Med Chem 26:436-439.
28. sα fusion protein. Eur J Biochem 255:369-382.
29. Seifert R and Wenzel-Seifert K (2002) Constitutive activity of G-protein-coupled receptors: cause of disease and common property of wild-type receptors. Naunyn Schmiedebergs Arch Pharmacol 366:381-416.
30. Sunahara RK, Dessauer CW, and Gilman AG (1996) Complexity and diversity of mammalian adenylyl cyclases. Annu Rev Pharmacol Toxicol 36:461-480.
31. sα with the cytosolic domains of mammalian adenylyl cyclase. J Biol Chem 272:22265-22271.
32. Takahashi N, Nemoto T, Kimura R, Tachikawa A, Miwa A, Okado H, Miyashita Y, Iino M, Kadowaki T, and Kasai H (2002) Two-photon excitation imaging of pancreatic islets with various fluorescent probes. Diabetes 51 (Suppl 1):S25-S28.
33. Tang WJ and Hurley JH (1998) Catalytic mechanism and regulation of mammalian adenylyl cyclases. Mol Pharmacol 54:231-240.
34. Tang WJ, Krupinski J, and Gilman AG (1991) Expression and characterization of calmodulin-activated (type I) adenylylcyclase. J Biol Chem 266:8595-8603.
35. sα. Methods Enzymol 345:198-206.
36. GTPγS. Science 278:1907-1916.
37. Tesmer JJ, Sunahara RK, Johnson RA, Gosselin G, Gilman AG, and Sprang SR (1999) Two-metal ion catalysis in adenylyl cyclases. Science 295:756-760.
38. Yamamoto M, Götz ME, Ozawa H, Luckhaus C, Saito T, Rösler M, and Riederer P (2000) Hippocampal level of neural specific adenylyl cyclase type I is decreased in Alzheimer's disease. Biochim Biophys Acta 1535:60-68.